J&J multiple myeloma drug Talvey cuts mortality risk by up to 53% in late-stage trial

J&J multiple myeloma drug Talvey cuts mortality risk by up to 53% in late-stage trial  Seeking Alpha

Summary aggregated from Seeking Alpha's public RSS feed. The full reporting belongs to Seeking Alpha — please read it on their site.